Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Solid-State 3D Electrochemiluminescence Platform: Depth-Tuned Ru Complexes Positioning for Label-Free High-Resolution Imaging.

ACS omega·2026
Same author

Sustainable biopolymers as protective coatings against indoor corrosion of bronze: A comparison among alginate, carboxymethyl cellulose, chitosan and pectin.

International journal of biological macromolecules·2026
Same author

Enhancing Non-small Cell Lung Cancer Susceptibility to Anti-PD-1/PD-L1 Therapy through PD-L1 Ligand-Ir(III) Complex Conjugates.

Cancer communications (London, England)·2026
Same author

Re: Markus Graefen, Fabian Falkenbach, Tobias Maurer, et al. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.09.4144.

European urology oncology·2025
Same author

Prostate radiotherapy in PEACE-1: is the event worth the treatment? - Authors' reply.

Lancet (London, England)·2025
Same author

Impact of Prostate Radiotherapy on Survival Outcomes in Patients with Metastatic Castration-sensitive Prostate Cancer: A Meta-analysis of Randomized Phase 3 Clinical Trials.

European urology oncology·2025

Related Experiment Video

Updated: Jan 6, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

625

EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative

Thomas B L Lam1, Steven MacLennan2, Peter-Paul M Willemse3

  • 1Academic Urology Unit, University of Aberdeen, Aberdeen, UK; Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK.

European Urology
|October 8, 2019
PubMed
Summary

This study developed consensus statements for deferred active treatment (DAT) in prostate cancer, addressing uncertainties in patient selection and monitoring. The findings aim to standardize care and guide clinical practice until further evidence emerges.

Keywords:
Active surveillance and monitoringClinical practice guidelinesConsensus group meetingConsensus statementsDeferred treatment with curative intentDelphi surveyEligibilityFollow-upLocalised prostate cancerOutcome measuresReclassification

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.0K

Related Experiment Videos

Last Updated: Jan 6, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

625
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.0K

Area of Science:

  • Oncology
  • Urology
  • Geriatric Oncology

Background:

  • Deferred active treatment (DAT) for early localized prostate cancer faces significant uncertainty in patient selection, follow-up, monitoring, and outcome prioritization.
  • Current practices exhibit considerable variation, necessitating standardization to improve patient care and research outcomes.

Framework:

  • A multi-phase approach was employed, including a systematic review, a two-round Delphi survey with healthcare practitioners (HCPs) and patients, and a consensus meeting.
  • This framework facilitated the development of consensus statements across all domains of DAT.

Implementation:

  • A large international panel of 109 HCPs and 16 patients participated in the Delphi survey.
  • A consensus meeting involving 32 HCPs and 3 patients further refined and voted on statements, achieving agreement on 93 out of 129 statements (72%).

Implications:

  • The developed consensus statements provide guidance for routine clinical practice and future research in deferred active treatment for prostate cancer.
  • These guidelines will help standardize care and reduce uncertainty until higher-level evidence from prospective studies becomes available.